类风湿关节炎市场：KOL 洞察

本报告考察了全球类风湿关节炎市场，并提供了市场概述，包括已上市的治疗方法、管道趋势和未来前景。

目录

执行摘要

治疗演算法

研究目标

• 市售治疗方法
  • 抗肿瘤坏死因子药物（Humira、Enbrel、Remicade、Simponi、Cimzia）
  • 白血球介素 6 抑制剂（Actemra/RoActemra、Kevzara）
  • Orencia（Abatacept，Bristol Myers Squibb）
  • Rituxan/Mabthera（Rituximab、Biogen/Roche）
  • Xeljanz（Tofacitinib，Pfizer）
  • Olumiant（Baricitinib、Incyte/Lilly）
  • Rinvoc（upadacitinib，AbbVie）
  • Giseleca（filgotinib，Galapagos）
• 管道疗法
  • Dazodarivep（HZN 4920；Amgen）
• 早期进展和其他可能影响 RA 治疗的因素
  • 关键见解摘要

附录

While use of anti-TNF therapies remains the first line biologic RA treatment choice, prescribing of IL-6 inhibitors has increased. But do KOLs prefer Roche's Actemra/RoActemra or Sanofi's Kevzara? Experts find Amgen's pipeline anti-CD40 ligand-Tn3 fusion protein dazodalibep to be intriguing, but do they see it finding a place in the crowded RA therapy market? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Companies Listed:

Table of Contents

Executive summary (8)

Treatment algorithm

Research objectives (86)

• Marketed therapies (67)
  • Anti-TNFs (Humira, Enbrel, Remicade, Simponi, Cimzia) (8)
  • Interleukin-6 inhibitors (Actemra/RoActemra, Kevzara) (10)
  • Orencia (abatacept; Bristol Myers Squibb) (10)
  • Rituxan/MabThera (rituximab; Biogen/Roche) (8)
  • Xeljanz (tofacitinib; Pfizer) (10)
  • Olumiant (baricitinib; Incyte/Lilly) (7)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Jyseleca (filgotinib; Galapagos) (6)
• Pipeline therapies (5)
  • dazodalibep (HZN 4920; Amgen) (5)
• Earlier-stage developments and other factors that may impact RA treatment (12)
  • Key insights summary (12)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)